North Carolina has won $38.8 million as part of a Medicaid fraud settlement from Johnson & Johnson.
The settlement resolves allegations that Johnson & Johnson improperly marketed some drugs, Attorney General Roy Cooper announced Wednesday.
Johnston & Johnston and it's subsidiary, Janssen Pharmaceuticals, improperly marketed the atypical anti-psychotic drugs Risperdal and Invega, according to the N.C. Department of Justice. North Carolina and other states alleged that those drugs were marketed for uses not approved by the Food and Drug Administration.
The $38.8 million that North Carolina will be receiving is part a $1.2 billion settlement with several states and the federal government.